{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:50:36Z","timestamp":1760061036858,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fingolimod is an oral drug for the escalation of treatment of relapsing\u2013remitting multiple sclerosis in patients with persistent disease activity on first\u2010line drugs or in patients with rapidly progressive severe relapsing\u2013remitting multiple sclerosis. An ultra\u2010high\u2010performance liquid chromatography\u2013tandem mass spectrometry method for determining the concentrations of fingolimod and its active metabolite fingolimod phosphate in whole blood has been developed and validated. The advantages of this method are the easy, fast and cheap sample preparation using protein precipitation from blood with a mixture of acetonitrile\u2013methanol (40:60, v\/v). Chromatographic separation was performed on a ultra\u2010high performance liquid chromatography BEH C<jats:sub>18<\/jats:sub> 1.7 \u03bcm (100\u2009\u00d7\u20092.1\u00a0mm) column. Two modes of ionization, electrospray ionization and atmospheric pressure chemical ionization, were tested and compared. For validation, the electrospray ionization mode was chosen. As internal standard, isotopically labeled fingolimod\u2010D<jats:sub>4<\/jats:sub> was used to quantify the analytes. The method was validated according to the rules of the European Medicines Agency. The coefficients of variation for fingolimod were in the range of 1.13\u201311.88%, and the recovery was 98.80\u2013106.00%. The coefficients of variation for fingolimod phosphate were in the range of 2.73\u20139.31%, and the recovery was 90.08\u2013107.00%. The method is quite easy and fast and can be used for routine analysis.<\/jats:p>","DOI":"10.1002\/bmc.5947","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T01:56:36Z","timestamp":1719453396000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liquid chromatography\u2013tandem mass spectrometry for determination of fingolimod and its active metabolite fingolimod phosphate in whole blood of patients with multiple sclerosis"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-3376","authenticated-orcid":false,"given":"Veronika","family":"Pesakova","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine University of Ostrava  Ostrava Czech Republic"},{"name":"Department of Clinical Pharmacology, Institute of Laboratory Medicine University Hospital Ostrava  Ostrava Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Brozmanova","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine University of Ostrava  Ostrava Czech Republic"},{"name":"Department of Clinical Pharmacology, Institute of Laboratory Medicine University Hospital Ostrava  Ostrava Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Sistik","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine University of Ostrava  Ostrava Czech Republic"},{"name":"Department of Clinical Pharmacology, Institute of Laboratory Medicine University Hospital Ostrava  Ostrava Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Kusnirikova","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine University of Ostrava  Ostrava Czech Republic"},{"name":"Department of Children Neurology, Department of Neurology University Hospital Ostrava  Ostrava Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Kacirova","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine University of Ostrava  Ostrava Czech Republic"},{"name":"Department of Clinical Pharmacology, Institute of Laboratory Medicine University Hospital Ostrava  Ostrava Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Grundmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine University of Ostrava  Ostrava Czech Republic"},{"name":"Department of Clinical Pharmacology, Institute of Laboratory Medicine University Hospital Ostrava  Ostrava Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.201000185"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.424"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.09.021"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.01.023"},{"key":"e_1_2_8_6_1","unstructured":"Guideline on bioanalytical method validation. (2015).European Medicines Agency.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf"},{"volume-title":"Identifying and overcoming matrix effects in drug discovery and development","year":"2012","author":"Hall T. G.","key":"e_1_2_8_7_1"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2015.08.012"},{"key":"e_1_2_8_9_1","unstructured":"MedChemExpress\u2014Master of Bioactive Molecules. (2013a).Fingolimod.https:\/\/www.medchemexpress.com\/fingolimod.html"},{"key":"e_1_2_8_10_1","unstructured":"MedChemExpress\u2014Master of Bioactive Molecules. (2013b).Fingolimod\u2010phosphate.https:\/\/www.medchemexpress.com\/fingolimod-phosphate.html"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.15406\/japlr.2016.02.00008"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115173"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.05.026"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3538"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3797\/scipharm.1408-08"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2015.11.042"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.09.009"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.01.003"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.035907"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.5947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:16:40Z","timestamp":1760041000000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.5947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/bmc.5947"],"URL":"https:\/\/doi.org\/10.1002\/bmc.5947","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"type":"print","value":"0269-3879"},{"type":"electronic","value":"1099-0801"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"2024-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5947"}}